-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Vaccitech (NASDAQ:VACC) Stock Price Down 2.2%
Vaccitech (NASDAQ:VACC) Stock Price Down 2.2%
Vaccitech plc (NASDAQ:VACC – Get Rating) traded down 2.2% on Wednesday . The company traded as low as $2.18 and last traded at $2.25. 30,744 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 153,387 shares. The stock had previously closed at $2.30.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley dropped their price target on shares of Vaccitech from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Monday, August 15th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Vaccitech in a research report on Monday, November 14th.
Get Vaccitech alerts:Vaccitech Stock Down 2.2 %
The business's 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $3.78. The stock has a market cap of $83.92 million, a P/E ratio of 7.03 and a beta of 0.10.
Vaccitech (NASDAQ:VACC – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.54. The company had revenue of $6.17 million for the quarter, compared to the consensus estimate of $5.43 million. As a group, research analysts forecast that Vaccitech plc will post 0.27 earnings per share for the current fiscal year.Institutional Trading of Vaccitech
A hedge fund recently bought a new stake in Vaccitech stock. Alphabet Inc. purchased a new stake in shares of Vaccitech plc (NASDAQ:VACC – Get Rating) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,513,644 shares of the company's stock, valued at approximately $4,844,000. Alphabet Inc. owned about 4.06% of Vaccitech at the end of the most recent quarter. Institutional investors own 12.86% of the company's stock.
About Vaccitech
(Get Rating)
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.
Featured Articles
- Get a free copy of the StockNews.com research report on Vaccitech (VACC)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.
Vaccitech plc (NASDAQ:VACC – Get Rating) traded down 2.2% on Wednesday . The company traded as low as $2.18 and last traded at $2.25. 30,744 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 153,387 shares. The stock had previously closed at $2.30.
纳斯达克(VAcc-Get Rating)周三下跌2.2%。该公司股价低至2.18美元，最新报2.25美元。午盘交易中，30,744股股票易手，较153,387股的平均成交量下降了80%。该股此前收盘价为2.30美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley dropped their price target on shares of Vaccitech from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Monday, August 15th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Vaccitech in a research report on Monday, November 14th.
一些股票研究分析师最近对该股进行了加码。在8月15日星期一的一份研究报告中，摩根士丹利将他们对Vaccitech股票的目标价从19.00美元下调至16.00美元，并对该公司设定了“增持”评级。11月14日，在一份研究报告中，HC Wainwright重申了买入评级，并对Vaccitech的股票发布了20.00美元的目标价。
Vaccitech Stock Down 2.2 %
华为股价下跌2.2%
The business's 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $3.78. The stock has a market cap of $83.92 million, a P/E ratio of 7.03 and a beta of 0.10.
该业务的50日简单移动均线切入位为2.64美元，200日简单移动均线切入位为3.78美元。该股市值为8392万美元，市盈率为7.03倍，贝塔系数为0.10。
Institutional Trading of Vaccitech
Vaccitech的机构交易
A hedge fund recently bought a new stake in Vaccitech stock. Alphabet Inc. purchased a new stake in shares of Vaccitech plc (NASDAQ:VACC – Get Rating) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,513,644 shares of the company's stock, valued at approximately $4,844,000. Alphabet Inc. owned about 4.06% of Vaccitech at the end of the most recent quarter. Institutional investors own 12.86% of the company's stock.
一家对冲基金最近购买了Vaccitech股票的新股份。Alphabet在最近提交给美国证券交易委员会的披露中称，该公司在第三季度增持了华为科技股份有限公司(纳斯达克代码：VACC-GET Rating)的股份。该机构投资者购买了1,513,644股该公司股票，价值约4,844,000美元。截至最近一个季度末，Alphabet持有华为约4.06%的股份。机构投资者持有该公司12.86%的股票。
About Vaccitech
关于Vaccitech
(Get Rating)
(获取评级)
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.
Vaccitech plc是一家临床阶段的生物制药公司，致力于发现和开发用于治疗和预防传染病和癌症的新型T细胞免疫疗法和疫苗。该公司的治疗计划包括VTP-300，这是治疗慢性乙肝感染的1/2a阶段临床试验；VTP-200，治疗人乳头瘤病毒感染的1/2a阶段临床试验；VTP-850，治疗前列腺癌的1/2阶段临床试验；以及VTP-600，治疗非小细胞肺癌的1/2a阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Vaccitech (VACC)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
- 免费获取StockNews.com关于Vaccitech的研究报告(VACC)
- 美联储轴心的问题不是是否，而是何时，这是为什么
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利好的3个股息之王
- 机构抛售Toll Brothers股票的涨势
- 低贝塔，高产量的坎贝尔汤公司很好
Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Vaccitech Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vaccitech和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧